EpiVax Oncology, Inc., a Providence, RI and NY-based precision cancer immunotherapy company, closed a $1.2M bridge financing.
Backers included NextWaveBio, Morningside Venture Investments, Accelerate NY Seed Fund and Horatio Ventures NYC.
The company intends to use the funds for continued advancement, and preparation for its Phase 1b clinical trial in bladder cancer.
Led by CEO and Co-Founder Gad Berdugo, MSc Eng., MBA, and Anne De Groot, MD, Scientific Founder, EpiVax Oncology is developing precision cancer immunotherapies based on Neo-Epitopes selected using Ancer™, its proprietary and validated, in silico, predictive algorithm. Using genetic Next Generation Sequencing of the tumors and the normal cells of each patient, followed by mutanome analysis, EO’s personalized therapeutic vaccines are customized and specifically designed for each individual patient.
EpiVax is preparing to enter into a Phase 1b clinical trial in bladder cancer using formulated synthetic long peptides based on Ancer™ derived Neo-Epitopes.
This financing serves as a bridge to the company’s planned Series A financing.